BDSX Biodesix

Biodesix to Participate in Upcoming Investor Conferences

Biodesix to Participate in Upcoming Investor Conferences

LOUISVILLE, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team will participate in two upcoming investor conferences:

TD Cowen's 46th Annual Health Care Conference

Fireside Chat Date: Tuesday, March 3, 2026

Fireside Chat Time: 2:30 PM ET

Location: Boston, MA

Barclays 28th Annual Global Healthcare Conference

Fireside Chat Date: Wednesday, March 11, 2026

Fireside Chat Time: 12:00 PM ET

Location: Miami, FL

The fireside chats will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at .

About Biodesix

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit .

Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc. 

Contacts:

Media:

Natalie St. Denis



1-720-925-9285

Investors:

Chris Brinzey



1-339-970-2843



EN
24/02/2026

Underlying

BDSXBiodesix

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biodesix

 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Biodesix Recognized as a Top Workplace for Third Consecutive Year Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture LOUISVILLE, Colo., April 09, 2026 (GLOBE NEWSWIRE) -- Biodesix is proud to announce that it has earned the prestigious 2026 USA TODAY Top Workplaces award. The award honors organizations with 150+ employees that have created exceptional, people-first cultures. The winners are determined by direct employee feedback captured through a confidential survey conducted by , the HR research and technology company behind the pr...

April 9, 2026 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting N...

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing LOUISVILLE, Colo., April 06, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that the company will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, from April 17 ...

April 6, 2026 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validati...

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient populations LOUISVILLE, Colo., March 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the . This milestone strengthens the clinical foundation for Nodify CDT® tests as a critical decision-support tool in the early detection of ...

March 20, 2026 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Hig...

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). "B...

February 26, 2026 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Participate in Upcoming Investor Conferences

Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team will participate in two upcoming investor conferences: TD Cowen's 46th Annual Health Care ConferenceFireside Chat Date: Tuesday, March 3, 2026Fireside Chat Time: 2:30 PM ETLocation: Boston, MA Barclays 28th Annual Global Healthcare ConferenceFireside Chat Date: Wednesday, March 11, 2026Fireside Chat Time: 12:00 PM ETLocation: Miami, FL The fireside chats will be...

February 24, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch